Cancer Clinical Trial
— ETAPOfficial title:
Effect of a Brief Therapeutic Patient Education Session on Physical Activity in Patients at the Onset of Cancer Therapy: A Randomized Controlled Trial
NCT number | NCT04665973 |
Other study ID # | ETAP |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | December 7, 2020 |
Est. completion date | July 29, 2022 |
Verified date | April 2024 |
Source | Cliniques universitaires Saint-Luc- Université Catholique de Louvain |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Despite significant evolution of cancer therapies from the early 20th century, these therapies are still associated with toxic effects that negatively impact the patient's performance status, quality of life and survival. The role of physical activity to counteract these side effects is acknowledged. However, cancer patients are often misinformed about the potential benefits of physical therapy during cancer therapy. In this context, the role of therapeutic patient education seems essential. Because of lack of time, therapeutic patient education (TPE) is often provided via an information booklet. However, the investigators assume that a face-to-face interview results in a greater impact on patient's behavior change (the level of physical activity during cancer therapy, in our case). This research project is designed to challenge this hypothesis. The investigators hypothesize that a brief oral educational session of 30 minutes provided at the very beginning of cancer therapy will enhance the physical activity level of our patients for at least 6 months, i.e. during their cancer therapy.
Status | Completed |
Enrollment | 98 |
Est. completion date | July 29, 2022 |
Est. primary completion date | July 29, 2022 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years to 84 Years |
Eligibility | Inclusion Criteria: - Adults aged between 18 and 84 years - Suffering from a first cancer, with the exception of the following cancers in the patient's history (provided that they have been successfully treated): - non-melanoma skin cancer, - carcinoma in situ of the uterine cervix - ductal carcinoma in situ. - Preserved performance status (ECOG scale = 1), - Starting one of the following systemic cancer therapies: - chemotherapy, - immunotherapy, - targeted therapies, - Able to understand and read French - Life expectancy of at least 1 year Exclusion Criteria: - Poor cognitive function (Mini-Mental State Examination = 24/30) - Having a recurrence of cancer, with the exception of the following cancers in the patient's history (provided that they have been successfully treated): - non-melanoma skin cancer, - carcinoma in situ of the uterine cervix, - ductal carcinoma in situ. |
Country | Name | City | State |
---|---|---|---|
Belgium | Cliniques universitaires Saint-Luc | Brussels |
Lead Sponsor | Collaborator |
---|---|
Cliniques universitaires Saint-Luc- Université Catholique de Louvain |
Belgium,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Changes in PA level | The PA level will be estimated in MET/h/week via the International Physical Activity Questionnaire (long form) validated in French in subjects aged 18-84 years. The questionnaire classifies the subject according to 3 activity levels: inactive, moderate, high |
At baseline and 6 months (at the occasion of a second follow-up visit set with the oncologist) after the start of the cancer therapy | |
Secondary | Changes in PA level | The PA level will be estimated in MET/h/week via the International Physical Activity Questionnaire (long form) validated in French in subjects aged 18-84 years. The questionnaire classifies the subject according to 3 activity levels: inactive, moderate, high |
At baseline and 3 months (at the occasion of a first follow-up visit set with the oncologist) after the start of the cancer therapy | |
Secondary | Changes in BMI | Body mass index (BMI) is measured as weight (kg) divided by height is meters squared (m²) | At baseline, 3 months and 6 months after the start of the cancer therapy | |
Secondary | Changes in fatigue | Fatigue is measured via the Functional Assessment of Chronic Illness Therapy - Fatigue scale (FACIT-F). The scale is a 40-item measure that assesses self-reported fatigue and its impact upon daily activities and function. The total score range from 0 to 160. The lower the score, the higher the fatigue. |
At baseline, 3 months and 6 months after the start of the cancer therapy | |
Secondary | Changes in quality of life | Quality of life is measured via the European Organization for Research and Treatment of Cancer quality of life questionnaire (EORTC QLQ-C30). The QLQ-C30 is composed of both multi-item scales and single-item measures. There are 30 items. These include five functional scales, three symptom scales, a global health status / QoL scale, and six single items. All single-item measures range in score from 0 to 100. A high score for a functional scale represents a high / healthy level of functioning, A high score for the global health status / QoL represents a high QoL, A high score for a symptom scale / item represents a high level of symptomatology / problems. |
At baseline, 3 months and 6 months after the start of the cancer therapy | |
Secondary | Changes in exercise capacity | Exercise capacity is measured via the 1-minute sit-to-stand test | At baseline, 3 months and 6 months after the start of the cancer therapy | |
Secondary | Changes in handgrip strength test | Handgrip strength test is measured via the JAMAR dynamometer | At baseline, 3 months and 6 months after the start of the cancer therapy | |
Secondary | Number of steps | The number of steps taken weekly via an application (ITO) downloaded on the patient's phone | At 3 months and 6 months after the start of the cancer therapy | |
Secondary | Number of patients entering a group of exercise medicine | The proportion of patient who started a program of exercise medicine will be calculated in each group | At 6 months after the start of the cancer therapy |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05346796 -
Survivorship Plan HEalth REcord (SPHERE) Implementation Trial
|
N/A | |
Recruiting |
NCT05094804 -
A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents
|
Phase 1/Phase 2 | |
Completed |
NCT04867850 -
Effect of Behavioral Nudges on Serious Illness Conversation Documentation
|
N/A | |
Enrolling by invitation |
NCT04086251 -
Remote Electronic Patient Monitoring in Oncology Patients
|
N/A | |
Completed |
NCT01285037 -
A Study of LY2801653 in Advanced Cancer
|
Phase 1 | |
Completed |
NCT00680992 -
Study of Denosumab in Subjects With Giant Cell Tumor of Bone
|
Phase 2 | |
Completed |
NCT00062842 -
Study of Irinotecan on a Weekly Schedule in Children
|
Phase 1 | |
Active, not recruiting |
NCT04548063 -
Consent Forms in Cancer Research: Examining the Effect of Length on Readability
|
N/A | |
Completed |
NCT04337203 -
Shared Healthcare Actions and Reflections Electronic Systems in Survivorship
|
N/A | |
Recruiting |
NCT04349293 -
Ex-vivo Evaluation of the Reactivity of the Immune Infiltrate of Cancers to Treatments With Monoclonal Antibodies Targeting the Immunomodulatory Pathways
|
N/A | |
Terminated |
NCT02866851 -
Feasibility Study of Monitoring by Web-application on Cytopenia Related to Chemotherapy
|
N/A | |
Active, not recruiting |
NCT05304988 -
Development and Validation of the EFT for Adolescents With Cancer
|
||
Completed |
NCT04448041 -
CRANE Feasibility Study: Nutritional Intervention for Patients Undergoing Cancer Surgery in Low- and Middle-Income Countries
|
||
Completed |
NCT00340522 -
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
|
||
Recruiting |
NCT04843891 -
Evaluation of PET Probe [64]Cu-Macrin in Cardiovascular Disease, Cancer and Sarcoidosis.
|
Phase 1 | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Completed |
NCT03109041 -
Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
|
Phase 1 | |
Completed |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
Terminated |
NCT01441115 -
ECI301 and Radiation for Advanced or Metastatic Cancer
|
Phase 1 | |
Recruiting |
NCT06206785 -
Resting Energy Expenditure in Palliative Cancer Patients
|